| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 16, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Other acquisition or disposition | -- | -- | 5,025 |
| May 16, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Other acquisition or disposition | -- | -- | 5,025 |
| Mar 06, 2023 |
General Counsel
Trans History: 4
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 39,270 |
| Mar 06, 2023 |
General Counsel
Trans History: 4
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | 350,000 | -- | -- |
| Mar 06, 2023 |
General Counsel
Trans History: 4
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | 117,810 | -- | -- |
| Feb 17, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Other acquisition or disposition | -- | -- | 5,025 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 124,794 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 560,000 | -- | 560,000 |
| Feb 15, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 841,615 |
| Feb 15, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,400,000 | -- | 1,400,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.